Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.55 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7790161 | 0.89 | LMNA (0.46) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL7314829 | 0.86 | LMNA (0.52) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL8745665 | 0.83 | HTT (0.61) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL7431205 | 0.81 | SLC1A3 (0.64) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL28088132 | 0.81 | SLC1A3 (0.61) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL7752769 | 0.80 | LMNA (0.67) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL7415154 | 0.79 | MTNR1A (0.49) | — | |
| SCHEMBL13055383 | 0.79 | LMNA (0.80) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL7378562 | 0.79 | LMNA (0.65) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL9536355 | 0.78 | MEN1 (0.48) | MAPTCTSSMEN1KMT2AKCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1516877-A1 | Amine derivatives as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | LMNA 1755/4885SMN1; SMN2 4034/4885SLC1A3 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.